Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: TUKYSA®
Sponsor: iOMEDICO AG
Collaborators: Seagen Inc.